Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: A novel antiproliferative agent with a potential therapeutic implication

Journal of Biological Chemistry

Volumn 287, Issue 36, 2012, Pages 30625-30640

  Dogra, Nilambra ^a   Mukhopadhyay, Tapas ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-CANCER AGENTS; ANTICANCER DRUG; ANTIPROLIFERATIVE AGENTS; CANCER CELL LINES; CANCER CELLS; CYCLINS; CYTOCHROME C; CYTOTOXIC EFFECTS; ENDOPLASMIC RETICULUM STRESS; FLUOROGENIC SUBSTRATE; GREEN FLUORESCENT PROTEIN; HUMAN LUNG CANCER CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; NON SMALL CELL LUNG CANCER; PLASMID ENCODING; PROTEASE ACTIVITIES; PROTEASOME INHIBITORS; PROTEASOMES; REACTIVE OXYGEN SPECIES; REGULATORY PROTEIN; TUMOR CELLS;

CELL CULTURE; CELL MEMBRANES; CYTOTOXICITY; GENES; OXYGEN; PROTEINS;

CELL DEATH;

ACTIVATING TRANSCRIPTION FACTOR 3; CHYMOTRYPSIN; CISPLATIN; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOCHROME C; ENHANCED GREEN FLUORESCENT PROTEIN; FENBENDAZOLE; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; I KAPPA B ALPHA; PACLITAXEL; PROTEASOME; PROTEIN NOXA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TRYPTASE; UBIQUITIN;

APOPTOSIS; ARTICLE; ATF3 GENE; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; GADD153 GENE; GENE; GROWTH INHIBITION; GRP78 GENE; HALF LIFE TIME; HUMAN; HUMAN CELL; IRE1ALPHA GENE; LUNG NON SMALL CELL CANCER; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NOXA GENE; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; TUMOR CELL; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 3; ANTINEMATODAL AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYTOCHROMES C; CYTOTOXINS; ENDORIBONUCLEASES; FENBENDAZOLE; HEAT-SHOCK PROTEINS; HUMANS; I-KAPPA B PROTEINS; MEMBRANE POTENTIALS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION FACTOR CHOP; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UBIQUITINATION;

EID: 84865763587     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.324228     Document Type: Article

References (58)

1. Adams, J. (2004) The proteasome. A suitable antineoplastic target. Nat. Rev. Cancer 4, 349-360
2. Hoeller, D., and Dikic, I. (2009) Targeting the ubiquitin system in cancer therapy. Nature 458, 438-444
3. Williamson, M. J., Silva, M. D., Terkelsen, J., Robertson, R., Yu, L., Xia, C., Hatsis, P., Bannerman, B., Babcock, T., Cao, Y., and Kupperman, E. (2009) The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol. Cancer Ther. 8, 3234-3243
4. Davies, A. M., Lara, P. N., Jr., Mack, P. C., and Gandara, D. R. (2007) Incorporating bortezomib into the treatment of lung cancer. Clin. Cancer Res. 13, s4647-s4651
5. Eckert, J., Conraths, F. J., and Tackmann, K. (2000) Echinococcosis. An emerging or re-emerging zoonosis? Int. J. Parasitol. 30, 1283-1294
6. Ammann, R. W., Ilitsch, N., Marincek, B., and Freiburghaus, A. U. (1994) Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group. Hepatology 19, 735-742
7. Müller, E., Akovbiantz, A., Ammann, R. W., Bircher, J., Eckert, J., Wissler, K., Witassek, F., and Wüthrich, B. (1982) Treatment of human echinococcosis with mebendazole. Preliminary observations in 28 patients. Hepatogastroenterology 29, 236-239
8. Marriner, S. E., Morris, D. L., Dickson, B., and Bogan, J. A. (1986) Pharmacokinetics of albendazole in man. Eur. J. Clin. Pharmacol. 30, 705-708
9. El-On, J. (2003) Benzimidazole treatment of cystic echinococcosis. Acta Trop. 85, 243-252
10. Lacey, E., and Watson, T. R. (1985) Structure-activity relationships of benzimidazole carbamates as inhibitors of mammalian tubulin, in vitro. Biochem. Pharmacol. 34, 1073-1077
11. Laclette, J. P., Guerra, G., and Zetina, C. (1980) Inhibition of tubulin polymerization by mebendazole. Biochem. Biophys. Res. Commun. 92, 417-423
12. Gull, K., Dawson, P. J., Davis, C., and Byard, E. H. (1987) Microtubules as target organelles for benzimidazole anthelmintic chemotherapy. Biochem. Soc. Trans. 15, 59-60
13. Robinson, M. W., McFerran, N., Trudgett, A., Hoey, L., and Fairweather, I. (2004) A possible model of benzimidazole binding to β-tubulin disclosed by invoking an interdomain movement. J. Mol. Graph. Model. 23, 275-284
14. Morris, D. L., Jourdan, J. L., and Pourgholami, M. H. (2001) Oncology 61, 42-46
15. Gao, P., Dang, C. V., and Watson, J. (2008) Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. J. Am. Assoc. Lab. Anim. Sci. 47, 37-40
16. Pourgholami, M. H., Cai, Z. Y., Badar, S., Wangoo, K., Poruchynsky, M. S., and Morris, D. L. (2010) Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole. BMC Cancer 10, 143
17. Mukhopadhyay, T., Sasaki, J., Ramesh, R., and Roth, J. A. (2002) Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin. Cancer Res. 8, 2963-2969
18. Sasaki, J., Ramesh, R., Chada, S., Gomyo, Y., Roth, J. A., and Mukhopadhyay, T. (2002) The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol. Cancer Ther. 1, 1201-1209
19. Nakamura, S., Gomyo, Y., Roth, J. A., and Mukhopadhyay, T. (2002) C terminus of p53 is required for G2 arrest. Oncogene 21, 2102-2107
20. Gold, R., Schmied, M., Giegerich, G., Breitschopf, H., Hartung, H. P., Toyka, K. V., and Lassmann, H. (1994) Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab. Invest. 71, 219-225
21. Jana, N. R., Zemskov, E. A., Wang, G., and Nukina, N. (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10, 1049-1059
22. Chomczynski, P., and Sacchi, N. (2006) The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Twenty-something years on. Nat. Protoc. 1, 581-585
23. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254
24. Nakamura, S., Roth, J. A., and Mukhopadhyay, T. (2000) Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol. Cell. Biol. 20, 9391-9398
25. Schreiber, E., Matthias, P., Müller, M. M., and Schaffner, W. (1989) Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells. Nucleic Acids Res. 17, 6419
26. Maxwell, S. A., and Mukhopadhyay, T. (1995) A novel NF-κB p65 spliced transcript lacking exons 6 and 7 in a non-small cell lung carcinoma cell line. Gene 166, 339-340
27. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825
28. 2/M promotes cyclin B-Cdc2 kinase activity. Mol. Cell. Biol. 25, 3364-3387
29. Chen, Q., Chai, Y. C., Mazumder, S., Jiang, C., Macklis, R. M., Chisolm, G. M., and Almasan, A. (2003) The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ. 10, 323-334
30. Fribley, A., Zeng, Q., and Wang, C. Y. (2004) Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell. Biol. 24, 9695-9704
31. Hiramatsu, N., Kasai, A., Hayakawa, K., Yao, J., and Kitamura, M. (2006) Real-time detection and continuous monitoring of ER stress in vitro and in vivo by ES-TRAP. Evidence for systemic, transient ER stress during endotoxemia. Nucleic Acids Res. 34, e93
32. Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., and Mori, K. (2001) XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107, 881-891
33. Szegezdi, E., Logue, S. E., Gorman, A. M., and Samali, A. (2006) Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 7, 880-885
34. Harding, H. P., Zhang, Y., Bertolotti, A., Zeng, H., and Ron, D. (2000) Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol. Cell 5, 897-904
35. Fels, D. R., Ye, J., Segan, A. T., Kridel, S. J., Spiotto, M., Olson, M., Koong, A. C., and Koumenis, C. (2008) Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res. 68, 9323-9330
36. Egger, L., Madden, D. T., Rhême, C., Rao, R. V., and Bredesen, D. E. (2007) Endoplasmic reticulum stress-induced cell death mediated by the proteasome. Cell Death Differ 14, 1172-1180
37. Egger, L., Schneider, J., Rhême, C., Tapernoux, M., Häcki, J., and Borner, C. (2003) Serine proteases mediate apoptosis-like cell death and phagocytosis under caspase-inhibiting conditions. Cell Death Differ. 10, 1188-1203
38. Lacey, E., and Gill, J. H. (1994) Biochemistry of benzimidazole resistance. Acta Trop. 56, 245-262
39. Almond, J. B., and Cohen, G. M. (2002) The proteasome. A novel target for cancer chemotherapy. Leukemia 16, 433-443
40. Bernassola, F., Ciechanover, A., and Melino, G. (2010) The ubiquitin proteasome system and its involvement in cell death pathways. Cell Death Differ. 17, 1-3
41. Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., and Brownell, J. E. (2011) Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug Discov. 10, 29-46
42. Orlowski, R. Z., and Kuhn, D. J. (2008) Proteasome inhibitors in cancer therapy. Lessons from the first decade. Clin. Cancer Res. 14, 1649-1657
43. Adams, J., and Kauffman, M. (2004) Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22, 304-311
44. Adams, J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417-421
45. Kip1 in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 14, 23-35
46. Lopes, U. G., Erhardt, P., Yao, R., and Cooper, G. M. (1997) p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem. 272, 12893-12896
47. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., Munshi, N. C., Richardson, P. G., Hideshima, T., and Anderson, K. C. (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. U.S.A. 99, 14374-14379
48. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N., Treon, S. P., and Anderson, K. C. (2002) Biologic sequelae of nuclear factor-κB blockade in multiple myeloma. Therapeutic applications. Blood 99, 4079-4086
49. Lezoualc'h, F., Sagara, Y., Holsboer, F., and Behl, C. (1998) High constitutive NF-κB activity mediates resistance to oxidative stress in neuronal cells. J. Neurosci. 18, 3224-3232
50. Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., Adams, J., and Anderson, K. C. (2002) NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 277, 16639-16647
51. Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., and Vogelstein, B. (1997) A model for p53-induced apoptosis. Nature 389, 300-305
52. Lomonosova, E., Ryerse, J., and Chinnadurai, G. (2009) BAX/BAK-independent mitoptosis during cell death induced by proteasome inhibition? Mol. Cancer Res. 7, 1268-1284
53. Nawrocki, S. T., Carew, J. S., Pino, M. S., Highshaw, R. A., Dunner, K., Jr., Huang, P., Abbruzzese, J. L., and McConkey, D. J. (2005) Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 65, 11658-11666
54. Nawrocki, S. T., Carew, J. S., Dunner, K., Jr., Boise, L. H., Chiao, P. J., Huang, P., Abbruzzese, J. L., and McConkey, D. J. (2005) Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res. 65, 11510-11519
55. Raj, L., Ide, T., Gurkar, A. U., Foley, M., Schenone, M., Li, X., Tolliday, N. J., Golub, T. R., Carr, S. A., Shamji, A. F., Stern, A. M., Mandinova, A., Schreiber, S. L., and Lee, S. W. (2011) Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475, 231-234
56. Trachootham, D., Alexandre, J., and Huang, P. (2009) Targeting cancer cells by ROS-mediated mechanisms. A radical therapeutic approach? Nat. Rev. Drug. Discov. 8, 579-591
57. Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P. J., Achanta, G., Arlinghaus, R. B., Liu, J., and Huang, P. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 10, 241-252
58. Huang, P., Feng, L., Oldham, E. A., Keating, M. J., and Plunkett, W. (2000) Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407, 390-395